Participate in a Huntington's Disease Clinical Trial or Study

KINECT-HD2 (Neurocrine) is a randomized, multicenter, open-label phase III clinical trial to evaluate the efficacy and safety of the orally active VMAT2 inhibitor Valbenazine in Huntington's Disease patients that present with active chorea.

ENROLLING NOW: The purpose of the study is to evaluate the long-term efficacy and safety of Valbenazine in HD subjects.

PROOF-HD is a randomized, multicenter, double-blind, placebo controlled, phase III study, conducted by Prilenia Therapeutics, evaluating the efficacy and safety of Pridopidine in patients with early stage HD. 

ENROLLING NOW: The purpose of the study is to evaluate the efficacy, safety, biomarker effects, and functional maintenance of Pridopidine compared with placebo in subjects with early stage HD.

DIMENSION (Sage Therapeutics) is a randomized, multicenter, double-blind, placebo-controlled
phase II clinical trial to evaluate the efficacy and safety of the compound SAGE-718 in early
Huntington's Disease patients.

ENROLLING NOW: The purpose of the study is to evaluate the efficacy and safety of SAGE-718
in early-HD subjects. The study will last approximately 3-4 months.

Huntington’s Study Group’s vUHDRS is an observational study that is investigating how
Huntington's Disease patients can manage having longitudinal neuropsychiatric testing done
virtually.

ENROLLMENT CLOSED: The purpose of the study is to observe participation for patients with
varying manifestations of Huntington's Disease. Key findings may help implement virtual visits
for testing where needed for patients who were previously unable to participate in longitudinal
studies.